SCAPIS Wellness profiling study

SNIC 2017/7-342


SNAC Small

Principal Investigator:

Linn Fagerberg


Kungliga Tekniska högskolan

Start Date:


End Date:


Primary Classification:

10610: Bioinformatics and Systems Biology (methods development to be 10203)



In 2012, SCAPIS started at Sahlgrenska University Hospital and the University of Gothenburg in collaboration with the Swedish Heart-Lung foundation with the overall aim to improve early discovery and treatment of possible cardiovascular and lung disease. In total, 30 000 individuals between the age of 50 to 64 years undergo a very thorough health examination including imaging of the heart, blood vessels and lungs. The SCAPIS trial is designed as a prospective population study with a comprehensive base-line examination and follow up via registry data. However, the design has limitations since the time between data collection and development of clinical events can be long and a number of environmental exposures will change and make it difficult to study associations with disease. In the SCAPIS Wellness Profiling study we aim to overcome this limitation by performing continuous monitoring of biomarkers after the initial base-line examination. The primary goal of the SCAPIS Wellness Profiling study is to develop a system for early detection of disease using continuous monitoring of critical biological parameters. To achieve this we will follow SCAPIS participants longitudinally after their baseline examination with frequent, repeated analyses of molecular markers in blood, urine and stool in combination with physical measurements and continuous monitoring of biological signals like sleep and activity. In the ongoing pilot study with approximately 100 individuals, we will first test the feasibility of the study procedure, develop the SCAPIS Wellness Profiling biobank and explore bioinformatics approaches for systems biology data integration. Proteomics (affinity proteomics, PEA, QPrEST), immunology (CyTOF), genetic (whole genome sequencing, RNA sequencing), metabolomics (plasma/urine) and microbiome analyses (16s RNA) will be used to understand the normal variation of molecular profiles in healthy individuals over time with the goal to facilitate a molecular definition of health.